Journals / Doğu Karadeniz Sağlık Bilimleri Dergisi / 2026 / Cilt: 5 Sayı: 2

Functional Hypothyroidism and Low T3 Syndrome: Clinical Significance, Metabolic Effects and Therapeutic Approaches

Fonksiyonel Hipotiroidi ve Düşük T3 Sendromu: Klinik Önemi, Metabolik Etkileri ve Tedavi Yaklaşımları

Erhan Özdemir(Trabzon Maçka Ömer Burhanoğlu Fizik Tedavi ve Rehabilitasyon Hastanesi)0009-0009-8520-4662
Pages
172–182
Publication Date
2026-07-31
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In conclusion, low T3 syndrome reflects a systemic metabolic adaptation and necessitates a holistic, multidisciplinary clinical approach.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Functional hypothyroidism is a heterogeneous clinical condition characterized by the presence of hypothyroid-like symptoms despite laboratory parameters remaining within reference ranges.
📊
Key Findings & Data:Within this spectrum, low T3 syndrome represents the most well-defined and biochemically demonstrable subtype, in which intrinsic thyroid gland function is preserved but peripheral thyroid hormone metabolism is altered.
💡
Conclusion & Impact:In conclusion, low T3 syndrome reflects a systemic metabolic adaptation and necessitates a holistic, multidisciplinary clinical approach.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:fonksiyonel hipotiroidi · düşük T3 sendromu · reverse T3

Abstract

Functional hypothyroidism is a heterogeneous clinical condition characterized by the presence of hypothyroid-like symptoms despite laboratory parameters remaining within reference ranges. Within this spectrum, low T3 syndrome represents the most well-defined and biochemically demonstrable subtype, in which intrinsic thyroid gland function is preserved but peripheral thyroid hormone metabolism is altered. It is characterized by decreased free T3 (fT3), elevated reverse T3 (rT3), and normal or suppressed thyroid-stimulating hormone (TSH) levels, and is generally considered an adaptive response to systemic illness, inflammation, chronic stress, and metabolic burden. Pathophysiologically, this condition is driven by alterations in deiodinase enzyme activity, specifically decreased type 1 and type 2 deiodinase activity and increased type 3 deiodinase activity. This shift reduces the conversion of thyroxine (T4) to the biologically active triiodothyronine (T3) while increasing the production of inactive rT3, ultimately leading to reduced metabolic rate and energy conservation. Major etiological factors include sepsis, chronic organ failure, trauma, malnutrition, and the use of certain medications such as glucocorticoids, amiodarone, and dopaminergic agents. Mitochondrial dysfunction, systemic inflammation, and micronutrient deficiencies—particularly iron, selenium, and zinc—play a central role in exacerbating the low T3 phenotype. Ferritin is especially critical due to its involvement in both thyroid hormone synthesis and peripheral conversion. From a diagnostic perspective, reliance solely on TSH is insufficient; a comprehensive evaluation incorporating clinical findings alongside fT3 and fT4 levels is required. Although rT3 measurement may have theoretical value, its routine clinical use is limited by issues of standardization and assay reliability. Therapeutically, current approaches emphasize management of the underlying condition rather than direct thyroid hormone replacement. Strategies targeting inflammation reduction, insulin resistance, stress modulation, and optimization of mitochondrial function are central. In conclusion, low T3 syndrome reflects a systemic metabolic adaptation and necessitates a holistic, multidisciplinary clinical approach.

Özet

Fonksiyonel hipotiroidi, klasik tanı kriterleriyle açıklanamayan ancak hipotiroidi benzeri semptomlarla seyreden heterojen bir klinik tabloyu ifade eder. Bu spektrum içerisinde en iyi tanımlanmış alt grup, tiroid bezinin intrinsik fonksiyonları korunmasına rağmen, periferik hormon metabolizmasındaki değişikliklerle karakterize olan düşük T3 sendromudur. Bu sendrom; düşük serbest T3 (fT3), artmış ters T3 (rT3) ve normal veya baskılanmış TSH düzeyleri ile tanımlanır ve genellikle sistemik hastalıklar, inflamasyon, kronik stres ve metabolik yüklenmeye karşı gelişen adaptif bir yanıt olarak değerlendirilir. Patofizyolojik olarak süreç; deiyodinaz enzim aktivitesindeki değişimlerle ilişkilidir; Tip 1 ve Tip 2 deiyodinaz aktivitesinin azalması ve Tip 3 deiyodinaz aktivitesinin artması, T4’ün aktif T3’e dönüşümünü azaltırken, inaktif rT3 üretimini artırır. Bu durum metabolik hızın düşmesi ve enerji tasarrufu ile sonuçlanır. Etiyolojide sepsis, kronik organ yetmezlikleri, travma, malnütrisyon ve bazı ilaçlar (glukokortikoidler, amiodaron, dopaminerjik ajanlar) önemli rol oynar. Mitokondriyal disfonksiyon, inflamasyon ve mikro besin eksiklikleri (özellikle demir, selenyum, çinko) düşük T3 paternini derinleştiren temel faktörlerdir. Ferritin düzeyleri, hem tiroid hormon sentezi hem de periferik dönüşüm açısından kritik öneme sahiptir. Tanıda yalnızca TSH’ye odaklanmak yetersiz olup, klinik bulgularla birlikte FT3 ve FT4 düzeylerinin bütüncül değerlendirilmesi gereklidir. rT3 ölçümü teorik olarak anlamlı olsa da, standardizasyon sorunları nedeniyle rutin kullanımda önerilmemektedir. Tedavi yaklaşımı; tiroid hormon replasmanından ziyade altta yatan patolojinin düzeltilmesine odaklanır. İnflamasyonun azaltılması, insülin direncinin düzeltilmesi, stres yönetimi ve mitokondriyal fonksiyonun desteklenmesi temel stratejilerdir. Sonuç olarak düşük T3 sendromu, sistemik hastalıkların biyokimyasal bir yansıması olup, multidisipliner ve bütüncül bir değerlendirme gerektirir.

🔖

Cite This Article

Özdemir, E. (2026). Functional Hypothyroidism and Low T3 Syndrome: Clinical Significance, Metabolic Effects and Therapeutic Approaches. Doğu Karadeniz Sağlık Bilimleri Dergisi, Cilt: 5 Sayı: 2, 172–182. https://doi.org/10.59312/ebshealth.1933914

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (27)

  1. Arrojo e Drigo, R., & Bianco, A. C. (2011). Type 2 deiodinase at the crossroads of thyroid hormone action. International Journal of Biochemistry & Cell Biology, 43(10), 1432–1441. https://doi.org/10.1016/j.biocel.2011.05.016
  2. Balbo, M., Leproult, R., & Van Cauter, E. (2010). Impact of sleep on HPA axis activity. International Journal of Endocrinology, 2010, 759234. https://doi.org/10.1155/2010/759234
  3. Barvalia, U., Amlani, B., & Pathak, R. (2014). Amiodarone-induced thyrotoxic thyroiditis: A diagnostic and therapeutic challenge. Case Reports in Medicine, 2014, 231651. https://doi.org/10.1155/2014/231651
  4. Basolo, A., Begaye, B., Hollstein, T., Vinales, K. L., Walter, M., Santini, F., Krakoff, J., & Piaggi, P. (2019). Effects of short-term fasting and different overfeeding diets on thyroid hormones in healthy humans. Thyroid, 29(9), 1209–1219. https://doi.org/10.1089/thy.2019.0237
  5. Bianco, A. C., Nunes, M. T., Hell, N. S., & Maciel, R. M. (1987). The role of glucocorticoids in the stress-induced reduction of extrathyroidal triiodothyronine generation in rats. Endocrinology, 120(3), 1033–1038. https://doi.org/10.1210/endo-120-3-1033
  6. Boelen, A., Kwakkel, J., & Fliers, E. (2011). Beyond low plasma T3: Local thyroid hormone metabolism during inflammation and infection. Endocrine Reviews, 32(5), 670–693. https://doi.org/10.1210/er.2011-0007
  7. Clinical Thyroidology for the Public. (2019). Thyroid function tests: A high proportion of serum rT3 tests are ordered by a relatively small number of providers in the United States. Clinical Thyroidology for the Public, 12(1), 11–12.
  8. de Vries, E. M., Fliers, E., & Boelen, A. (2015). The molecular basis of the non-thyroidal illness syndrome. Journal of Endocrinology, 225(3), R67–R81. https://doi.org/10.1530/JOE-15-0133
  9. Duberley, K. E., et al. (2014). Effect of coenzyme Q10 supplementation on mitochondrial function. International Journal of Biochemistry & Cell Biology, 50, 60–63. https://doi.org/10.1016/j.biocel.2014.02.003
  10. Farwell, A. P. (2013). Nonthyroidal illness syndrome. Current Opinion in Endocrinology, Diabetes and Obesity, 20(5), 478–484. https://doi.org/10.1097/01.med.0000433069.09294.e8
  11. Fliers, E., Bianco, A. C., Langouche, L., & Boelen, A. (2015). Thyroid function in critically ill patients. The Lancet Diabetes & Endocrinology, 3(10), 816–825. https://doi.org/10.1016/S2213-8587(15)00225-9
  12. Hagen, T. M., Ingersoll, R. T., Lykkesfeldt, J., Liu, J., Wehr, C. M., Vinarsky, V., Bartholomew, J. C., & Ames, B. N. (1999). (R)-α-lipoic acid improves mitochondrial function. FASEB Journal, 13(2), 411–418. https://doi.org/10.1096/fasebj.13.2.411
  13. Haugen, B. R. (2009). Drugs that suppress TSH or cause central hypothyroidism. Best Practice & Research Clinical Endocrinology & Metabolism, 23(6), 793–800. https://doi.org/10.1016/j.beem.2009.08.003
  14. He, C.-J., Zhu, C.-Y., Fan, H.-Y., Qian, Y.-Z., Zhai, C.-L., & Hu, H.-L. (2023). Low T3 syndrome predicts more adverse events in patients with hypertrophic cardiomyopathy. Clinical Cardiology, 46(12), 1569–1577. https://doi.org/10.1002/clc.24156
  15. Hercbergs, A., Mousa, S. A., & Davis, P. J. (2018). Nonthyroidal illness syndrome and thyroid hormone actions at integrin αvβ3. The Journal of Clinical Endocrinology & Metabolism, 103(4), 1291–1295. https://doi.org/10.1210/jc.2017-01939
  16. Iervasi, G., Pingitore, A., Landi, P., Raciti, M., Ripoli, A., Scarlattini, M., L’Abbate, A., & Donato, L. (2003). Low-T3 syndrome: A strong prognostic predictor of death in patients with heart disease. Circulation, 107(5), 708–713. https://doi.org/10.1161/01.cir.0000048124.64204.3f
  17. Jonklaas, J., et al. (2014). Guidelines for the treatment of hypothyroidism. Thyroid, 24(12), 1670–1751. https://doi.org/10.1089/thy.2014.0028
  18. Kelly, C. J., Couch, R. K., Ha, V. T., & Bodart, C. M. (2023). Iron status influences mitochondrial disease progression in complex I-deficient mice. eLife. https://doi.org/10.7554/eLife.75825
  19. Kerksick, C., & Willoughby, D. (2005). The antioxidant role of glutathione and N-acetyl-cysteine. Journal of the International Society of Sports Nutrition, 2(2), 38–44. https://doi.org/10.1186/1550-2783-2-2-38
  20. Khan, T., Waseem, R., Zehra, Z., Aiman, A., Bhardwaj, P., Ansari, J., Hassan, M. I., & Islam, A. (2022). Mitochondrial dysfunction: Pathophysiology and mitochondria-targeted drug delivery approaches. Pharmaceutics, 14(12), 2657. https://doi.org/10.3390/pharmaceutics14122657
  21. Liu, M., et al. (2019). Magnesium supplementation improves mitochondrial function. JCI Insight, 4(1), e123182. https://doi.org/10.1172/jci.insight.123182
  22. Murphy, M. P. (2008). How mitochondria produce reactive oxygen species. Biochemical Journal, 417(1), 1–13. https://doi.org/10.1042/BJ20081386
  23. Ronaldson, A., et al. (2018). The effects of SSRI administration on cortisol secretion. Psychopharmacology, 235(12), 3415–3422. https://doi.org/10.1007/s00213-018-5050-1
  24. Rozo-Paz, G., Ruiz-Forero, C. M., Suárez-Mera, J. D., Monsalve-Duarte, G., & Kattah Calderón, W. (2025). Levodopa induces thyroid function regulation in a patient with thyroid hormone resistance and Parkinson’s disease: A case report. Frontiers in Endocrinology, 16, 1536372. https://doi.org/10.3389/fendo.2025.1536372
  25. Sharma, A. K., Basu, I., & Singh, S. (2018). Efficacy and safety of ashwagandha root extract in subclinical hypothyroid patients. Journal of Alternative and Complementary Medicine, 24(3), 243–248. https://doi.org/10.1089/acm.2017.0183
  26. Souza, L. S. A. L., et al. (2025). Selenium nutritional status and thyroid dysfunction. Archives of Endocrinology and Metabolism, 69(1). https://doi.org/10.20945/2359-4292-2023-0348
  27. Tsigos, C., Kyrou, I., Kassi, E., & Chrousos, G. P. (2020). Stress: Endocrine physiology and pathophysiology. Endotext.